Treatment of pathological stage T3N+M0 bladder cancer: the case for observation

Semin Urol. 1993 May;11(2):64-8.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / mortality
  • Carcinoma, Transitional Cell / pathology
  • Cisplatin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Gallium / administration & dosage
  • Humans
  • Methotrexate / administration & dosage
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Organoplatinum Compounds / administration & dosage
  • Prognosis
  • Survival Rate
  • Treatment Outcome
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / pathology

Substances

  • Organoplatinum Compounds
  • didimethylsulfoxide dichloroplatinum(II)
  • Doxorubicin
  • Cyclophosphamide
  • Carboplatin
  • Gallium
  • Cisplatin
  • gallium nitrate
  • Methotrexate

Supplementary concepts

  • CISCA protocol